Clinical trial
Aminocamptothecin in Treating Patients With T-cell Lymphoma
NCT00002635 · Yale University, Other · Completed
Key facts
| NCT number | NCT00002635 |
|---|---|
| Title | Aminocamptothecin in Treating Patients With T-cell Lymphoma |
| Official title | PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, aminocamptothecin |
| Enrollment | 12 |
| Start date | May 1, 1995 |
| Primary completion | Apr 1, 2000 |
| Completion | Apr 1, 2000 |
| First posted | Aug 11, 2004 |
| Last update posted | Jul 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: